Business Update

Introgen Therapeutics pursues dual listing on London Stock Exchange

Published in Vaccine Weekly, July 6th, 2005

Introgen Therapeutics, Inc. (INGN) announced that its management has been authorized to take steps to effect a dual listing for the company on both the NASDAQ and London Stock Exchange (LSE).

The LSE listing decision reflects Introgen's ongoing discussions with potential international distribution partners, including European entities, as well as the expansion of its European investor base. In December 2004, Introgen placed shares with European institutions to increase its already significant European investor base. Introgen's first underwritten offering in 1997 was sold exclusively to European institutions.

In addition, the Company recently...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-07-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry